Decreased Thymidine Kinase Levels in Peripheral Blood Cells from HIV-Seropositive Individuals: Implications for Zidovudine Metabolism

AIDS Research and Human Retroviruses

Volumn 11, Issue 7, 1995, Pages 805-811

  Jacobsson, Bengt ^a   Britton, Sven ^a   Quimin, Q ^b   Karlsson, Anna ^b   Eriksson, Staffan ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

THYMIDINE KINASE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CELL CYCLE; CELLS, CULTURED; FLOW CYTOMETRY; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; KINETICS; LYMPHOCYTES; REFERENCE VALUES; THYMIDINE KINASE; ZIDOVUDINE;

EID: 0029023744     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1995.11.805     Document Type: Article

References (33)

1. Balzarini J, Baba M, Pauwels R, Herdewijn P, and De Clerq E: Anti-retrovirus activity of 3'-fluoro-and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues. Biochem Pharmacol 1988;37:2847-2856.
2. Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richraan DD, Fuchs E, Meriganet TC, Reichman RC, Gold J, Steigbigel N, Leoung GS, Rasheed S, and Tsiatis A: A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired inununodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1990; 323:1009-1014.
3. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding O, Laskin L, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, Phil D, and King D: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-191.
4. Mitsuya H and Broder S: Strategies for antiviral therapy in AIDS. Nature (London) 1987;325:773-778.
5. Mitsuya H and Broder S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type Ill/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911-1915.
6. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, and Broder S: 3'-Azido-3'-de-oxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type Ill/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-7100.
7. Yarchoan R, Mitsuya H, Thomas RV, St Clair MH, Lehrman SN. Gallo RC, Bolognesi D, Barry DW, and Broder S: In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science 1989;245:412-415.
8. Yarchoan R, Pemo CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, Mitsuya H, Pluda JM, Lawley TJ, Leuther M, Safai B, Collins JM, Myers CM, and Broder S: Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76-81.
9. Yarchoan R. Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrmanal SN, Blum RM, Barry DW, Shearer GM, Fischl MA, Mitsuya H, Gallo RC, Collins JM, Bolognesi DP, Myers CE, and Broder S: Administration of S'-azido-S'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1:575-580.
10. Eriksson S, Kierdaszuk B, Munch PB, Oberg B, and Johansson NG: Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991; 176:586-592.
11. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, and Barry DW: Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-8337.
12. Huang P, Farquhar D, and Plunket W: Selective action of 3'-azido-3'-deoxythymidine-5'-triphosphate on viral reverse transcriptase and human DNA polymerases. J Biol Chem 1990;265:11914-11918.
13. St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, and Langlois AJ: 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human inununo deficiency virus reverse transcriptase. Antlmicrob Agent Chemother 1987;31: 1972-1977.
14. Munch PB, Cloos L, Tyrsted G, and Eriksson S: Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991;266:9032-9038.
15. Eriksson BF, Chu CK, and Schinazi RF: Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate. Antimicrob Agents Chemother 1989;33:1729-1734.
16. Amer ES, Spasokoukotskaja T, and Eriksson S: Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 1992;188:712-718.
17. Amer ES, Valentin A, and Eriksson S: Thymidine and 3'-azido-3'-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J Biol Chem 1992;267:10968-10975.
18. Pemo CF, Yarchoan R, Cooney DA, Hartman NR, Webb DS, Hao Z, Mitsuya H, Johns DG, and Broder S: Inhibition of human immunodeficiency vims (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med 1988;168:1111-1125.
19. Klecker RJ, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S, and Myers CE: Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987;41:407-412.
20. Tomevik Y, Jacobsson B, Britton S, and Eriksson S: Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells. Aids Res Hum Retrovimses 1991;7: 751-759.
21. Boucher CA, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, and Tersmette M: HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992;6:1259-1264.
22. Larder BA, Darby G, and Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
23. Tribukait B, Moberger B, and Zetterberg A: Methodological aspects on rapid-flow cytofluorometry for DNA-analysis of human urinary bladder cells. In: First International Symposium on Pulse Cytophotometry (Haanen H Wessel, ed.). Ghent, Belgium, 1975, p. 50. [Abstract]
24. He Q, Skog S, Eriksson S. Wang N, and Tribukait B: Regulation of thymidine kinase 1 levels in G2 phase of the cell cycle as determined by inmiunoquantification. 1994 (submitted).
25. Pharmacia LKB Biotechnology System Handbook. 210 Multiphor II Electrophoresis System, 1989, p. 113-124, Uppsala, Sweden.
26. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, and Shearer GM: Detection of three distinct pattems of T-helper cell dysfunction in asymptomatic, human immunodeficiency vims-seropositive patients. J Clin Invest 1989;84:1892-1899.
27. Johnson JP, Hebei R, and Shinaberry R: Lymphoproliferative responses to mitogen and antigen in HIV-infected children. AIDS Res Hum Retrovimses 1991;7:781-786.
28. Jacobsson B, Britton S, and Eriksson S: Expression of thymidy-late kinase is decreased in PBMC from HIV infected individuals (in preparation).
29. Green DR, Bissonnette RP, Glynn JM, and Shi Y: Activation-induced apoptosis in lymphoid systems. Semin Inmiunol 1992; 4:379-388.
30. Hofmann B, Nishanian P, Nguyen T, Liu M, and Fahey JL: Restoration of T-cell function in HTV infection by reduction of intracellular cAMP levels with adenosine analogues. AIDS 1993; 7:659-664.
31. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, and Fahey JL: Semm neopterin changes in HIV-infected subjects: Indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr 1989;2:70-76.
32. Avramis VI, Kwock R, Solorzano MM, and Gomperts E: Evidence of in vitro development of dmg resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 1993;6:1287-1296.
33. Ogris E, Rotheneder H, Mudrak I, Pichler A, and Wintersberger E: A binding site for transcription factor E2F is a target for trans activation of murine thymidine kinase by polyomavims large T antigen and plays an important role in growth regulation of the gene. J Virol 1993;67:1765-1771.